Skip to main content
. 2022 Jul 6;6(13):3911–3920. doi: 10.1182/bloodadvances.2021006520

Table 3.

CT and PET-CT response assessment at 6 months (end of combination therapy)

Method of assessment N evaluable patients CR, % 95% CI (Clopper Pearson) ORR, % 95% CI (Clopper Pearson)
CT 24 25.0 (9.8; 46.7%) 87.5 (67.6; 97.3%)
PET/CT 19 68.4 (43.4; 87.4%) 84.2 (60.4; 96.6%)